

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Aisling Capital, LLC, Lender Representative		03/18/2013	LIMITED LIABILITY COMPANY: DELAWARE

RECEIVING PARTY DATA	
Name:	CeNeRx BioPharma, Inc.
Street Address:	270 Cornerstone Drive Suite 103
City:	Cary
State/Country:	NORTH CAROLINA
Postal Code:	27519
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 3		
Property Type	Number	Word Mark
Registration Number:	3662094	CENERX
Registration Number:	3687175	TRIRIMA
Serial Number:	77807249	AYRENE

CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	919-781-4000
Email:	lblackwell@wyrick.com
Correspondent Name:	Linda Blackwell
Address Line 1:	4101 Lake Boone Trail Suite 300
Address Line 2:	Wyrick Robbins Yates & Ponton LLP
Address Line 4:	Raleigh, NORTH CAROLINA 27607

ATTORNEY DOCKET NUMBER:	20515.1 LFB
--------------------------------	-------------

OP \$90.00 3662094

NAME OF SUBMITTER:	Lloyd Appel, CFO
Signature:	/Lloyd Appel/
Date:	03/19/2013
Total Attachments: 6 source=Aisling US PTO Release#page1.tif source=Aisling US PTO Release#page2.tif source=Aisling US PTO Release#page3.tif source=Aisling US PTO Release#page4.tif source=Aisling US PTO Release#page5.tif source=Aisling US PTO Release#page6.tif	

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

THIS RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST made and entered effective as of March 18, 2013, by the below signatory hereto, the "Lender Representative") in favor of CeNeRx BioPharma, Inc., a Delaware corporation, (the "Borrower").

WHEREAS, Perseus-Soros Biopharmaceutical Fund, L.P., L Capital Partners SBIC, LP, F VIII Omega LLC, I. Wistar Morris, III, A.M. Pappas Life Science Ventures III, LP, PV III CEO Fund, LP, and MB 157, LLC (collectively, the "Lenders") and Borrower were parties to a certain Intellectual Property Security Agreement dated as of November 21, 2011 (the "Security Agreement") and recorded in the United States Patent and Trademark Office on November 28, 2011 at Reel 027284/ Frame 0495, and on November 29, 2011 at Reel 4670/ Frame 0513, as amended at Reel 4795/ Frame 0899, under which Borrower granted Lenders a security interest in Borrower's trademarks and patents, including but not limited to the trademarks and patents listed on Schedule A hereto (the "Security Interest"); and

WHEREAS, Lenders now desire to release and terminate the Security Interest as to the trademarks and patents listed on Schedule A.

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, the Lenders hereby terminate the Security Interest and release to Borrower all interest which Lenders possess or are otherwise entitled to in the patents and trademarks listed on Schedule A hereto by virtue of such Security Agreement.

[Signature page follows.]

IN WITNESS WHEREOF, the undersigned has executed this Release of Intellectual Property Security Interest as of the date first above written.

LENDER REPRESENTATIVE:

AISLING CAPITAL, LLC

By: _____

Name: _____

Title: _____

[Handwritten Signature]
Michael Appel
CEO

SCHEDULE A

Copyrights

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
NONE	N/A	N/A

PATENTS

<u>Title</u>	<u>Patent/Patent Application Number (Publication Number)</u>	<u>Issue/Filing Date</u>
Methods of treating Rett Syndrome	12/117,586 20080280983	05/08/2008
Dialkylamino Alkyl Esters of Pivagabine as Medicaments for the Treatment of Central Nervous System Disorders	US 7,632,836 20090111813	12/15/2009
Polymorphic Form Of Fluoro-7-(2,2,2-Trifluoroethoxy) Phenoxathiin-10,10-Dioxide	US 7,812,050 11/773,892 20080009542	10/12/2010 07/05/2007 01/10/2008
Oral Enteric Antidepressant Formulation	13/143,408 20120003303	01/08/2010 01/05/2012
Oral Sustained Release Antidepressant Formulation	13/143,403 20120003274	01/08/2010 01/05/2012
Pharmaceutical Compounds	12/330,434 20090081123	12/08/2008
Methods of treating Rett Syndrome	PCT/US2008/063129	11/20/2008
Dialkylamino Alkyl Esters of Pivagabine as Medicaments for the Treatment of Central Nervous System Disorders	PCT/US2007/024547	06/05/2008
Polymorphic Form Of Fluoro-7-(2,2,2-Trifluoroethoxy) Phenoxathiin-10,10-Dioxide	PCT/US2007/015533	01/17/2008
Oral Antidepressant Formulation with Reduced Excipient Load	US 8,313,766 12/860,358 20110206769	11/20/2012 08/20/2010 08/25/2011

TRADEMARKS

<u>Description</u>	<u>Registration/Application Number</u>	<u>Registration/Application Date</u>
CENERX	3,662,094	07/28/2009
CENERX (Canada)	1,333,088	01/29/2007
MERIMA	77/467,853	05/07/2008
MYRIMA	77/467,852	05/07/2008
ATYRIMA	77/467,850	05/07/2008
TRIRIMA	3,687,175	09/22/2009
ATYREMA	77/478,437	05/19/2008
TYRIMA	77/094,042	01/29/2007
AYRENE	77/807,249	08/18/2009

SCHEDULE D

Mask Works

Description

Registration/
Application
Number

Registration/
Application
Date

NONE

N/A

N/A